Reports from the courts: the latest cases in Mansfield, Ashfield and Bassetlaw
Here are some of the latest cases to be heard at Mansfield Magistrates Court.
Source: hucknalldispatch.co.uk
Catherine Auld News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Catherine Auld. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Catherine Auld Today - Breaking & Trending Today
Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting
/PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and...
Source: prnewswire.com
.jpg)
NA Proactive news snapshot: Steppe Gold Limited, QC Copper and Gold Inc, Altiplano Metals Inc, GreenBank Capital Inc, Victory Square Technologies Inc, WeedMD Inc, Organic Garage Ltd, Xigem Technologies Corporation, Aequus Pharmaceuticals Inc, Lingo Media
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Source: proactiveinvestors.com
NA Proactive news snapshot: Real Luck Group Ltd,  Steppe Gold Limited, QC Copper and Gold Inc, Altiplano Metals Inc, GreenBank Capital Inc, Victory Square Technologies Inc, WeedMD Inc, Organic Garage Ltd, Xigem Technologies Corporation, Aequus Pharmaceuti
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Source: proactiveinvestors.com
NA Proactive news snapshot: Mydecine Innovations Group Inc, Aion Therapeutic Inc, EVmo Inc, Alpine 4 Holdings Inc, Dalrada Corporation , Ayurcann Holdings Corp, HempFusion Wellness Inc, Fireweed Zinc Ltd, Fury Gold Mines Ltd, Ridgeline Minerals Corp, AIM
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Mydecine Innovations Group Inc (NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) announced that it ended the first quarter of 2021 with cash and equivalents of C$11.3 million, which the company said will help it advance its intellectual property portfolio, build out its clinical trial calendar, expand its European operations and develop its technology division. As well, Mydecine said its strategic partnerships are expected to expand its drug development...
Source: proactiveinvestors.com